4.4 Article

The Impact of the 13-Valent Pneumococcal Conjugate Vaccine on Otitis Media-Related Antibiotic Use Among Young Children in Tennessee, USA

Journal

OPEN FORUM INFECTIOUS DISEASES
Volume 9, Issue 3, Pages -

Publisher

OXFORD UNIV PRESS INC
DOI: 10.1093/ofid/ofac019

Keywords

otitis media; antibiotic use; pneumococcal conjugate vaccines

Funding

  1. Building Interdisciplinary Research Careers in Women's Health (BIRCWH) program - National Institutes of Health (NIH) [5K12HD043483]
  2. National Institute on Drug Abuse [K01DA051683]
  3. Sanofi Pasteur
  4. Vanderbilt Trans-Institutional Program Vanderbilt Study of Antimicrobial Resistance
  5. National Institutes of Health ([NIH] NIAID) [K24AI148459]

Ask authors/readers for more resources

The introduction of PCV13 vaccine led to reductions in otitis media among US children, but its impact on antibiotic use for otitis media remained stable among Tennessee children under 2 years of age.
Otitis media (OM) is a leading cause of pediatric antibiotic use. Introduction of the 13-valent pneumococcal conjugate vaccine (PCV13) led to reductions in OM among US children, though its impact on OM-related antibiotic use remains unclear. Among 499 683 Tennessee children <2 years of age, the OM-related antibiotic fill rate was stable after PCV13 introduction.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available